Drug Type Biological products |
Synonyms mANP, ZD-100 |
Target |
Mechanism Aldosterone antagonists |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Resistant hypertension | Phase 2 | - | 01 Jul 2024 | |
Resistant hypertension | Phase 2 | - | 01 Jul 2024 | |
Chronic Kidney Diseases | Phase 2 | US | 01 Nov 2022 | |
Heart Failure | Phase 2 | US | 01 Nov 2022 |
Phase 1 | 22 | zcjkvvuayo(prohepvjrl) = bjdngfsxww rcxbatnmmi (pvomjqbrsy ) View more | - | 26 Aug 2023 | |||
Phase 1 | - | mcuiqztkxl(btddtmciho) = ptgqrtftli jyoudcybcn (gqegljtejn ) View more | - | 28 Aug 2016 | |||
Placebo | amjmteaniy(rekwbtfcqg) = ombnvghgzb ahtizuuvmv (mdgifkwsaq ) View more |